VOR (Vor Biopharma) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


VOR Vor Biopharma Inc VOR
32 GF Score
Price $19.14
! 3 Warning Signs
View Full Analysis

What is Vor Biopharma Short-Term Debt?

Vor Biopharma VOR -3.09% 32 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Vor Biopharma's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Vor Biopharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vor Biopharma Short-Term Debt Related Terms

Vor Biopharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Vor Biopharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vor Biopharma Short-Term Debt Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vor Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VOR
32GF Score
Vor Biopharma Inc VOR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Vor Biopharma (VOR) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Vor Biopharma's Short-Term Debt too high?
Vor Biopharma's current Short-Term Debt is $0.00 Mil. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's Short-Term Debt compare to ODTX and ANNX?
Vor Biopharma's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Vor Biopharma's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Vor Biopharma (VOR), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vor Biopharma Business Description

Address 500 Boylston Street, Suite 1350, Boston, MA, USA, 02116
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score

Get the complete analysis for VOR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.14
Price